絞り込み

16644

広告

Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.

著者 Arevalo JF , Fromow-Guerra J , Quiroz-Mercado H , Sanchez JG , Wu L , Maia M , Berrocal MH , Solis-Vivanco A , Farah ME ,
Ophthalmology.2007 Apr ; 114(4):743-50.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Retina and Vitreous Service, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela. arevalojf@movistar.net.ve

スターを付ける スターを付ける     (218view , 0users)

Full Text Sources

Medical

Miscellaneous

Other Literature Sources

To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME).
PMID: 17398322 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード